Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2022-09-27 Interim / Quarterly Rep…
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
THERANEXUS ANNOUNCES ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2022
Interim / Quarterly Report Classification · 1% confidence The document is a formal announcement of financial results for the first half of 2022. It contains a summary of the income statement, detailed management commentary on financial performance, and operational updates. Since it provides substantive financial data for an interim period (H1 2022) and is not merely an announcement of a report's availability, it qualifies as an Interim/Quarterly Report (IR). H1 2022
2022-09-27 English
THERANEXUS ANNONCE SES RÉSULTATS FINANCIERS DU PREMIER SEMESTRE 2022
Interim / Quarterly Report Classification · 1% confidence The document is a formal announcement of financial results for the first half of 2022 (S1-2022). It includes a summary table of financial performance (income statement items) and detailed management commentary on the results, cash position, and operational highlights. Since it contains substantive financial data and analysis for an interim period (half-year), it qualifies as an Interim/Quarterly Report (IR) rather than just an earnings release or a publication announcement. H1 2022
2022-09-27 French
Theranexus et la fondation BBDF finalisent le recrutement de l'étude de phase I/II évaluant Batten-1 dans la maladie de Batten
Regulatory Filings Classification · 1% confidence The document is a press release dated September 8, 2022, announcing that Theranexus and the BBDF Foundation have finalized recruitment for a Phase I/II clinical study evaluating the drug Batten-1 for Batten disease. It discusses clinical trial progress, future development plans (Phase II/III study in 2023), and provides company/disease background. Crucially, the document ends with a section titled "Prochaine publication financière: Mardi 27 septembre 2022: Résultats financiers du premier semestre 2022". This indicates the document itself is an announcement about clinical progress, not the financial report itself. Since it is a general corporate/clinical update that doesn't fit specific categories like ER (Earnings Release), LTR (Legal), or CAP (Financing), and it is not a short announcement pointing to an attached report (RPA), it falls best under the general 'Regulatory Filings' category (RNS) as a significant corporate event announcement, or potentially an Investor Presentation (IP) if it were structured as a deck, but given the format, RNS is the most appropriate catch-all for non-standard, material announcements.
2022-09-08 French
Theranexus and BBDF finalize recruitment for phase I/II trial to evaluate Batten-1 in Batten disease
Regulatory Filings Classification · 1% confidence The document is a press release dated September 8, 2022, announcing the finalization of recruitment for a Phase I/II clinical trial for the drug Batten-1. It contains key business updates, quotes from management, and information about the disease and the companies involved (Theranexus and BBDF). Crucially, near the end, it states: "Next financial publication: Tuesday 27 September 2022: First half 2022 financial results". This structure—a news announcement detailing operational progress and explicitly pointing to a future financial results release—is characteristic of an Earnings Release (ER) or a general press release that is not a full statutory filing (like 10-K or IR). Since it is announcing operational progress (trial recruitment) rather than the actual financial results themselves, it functions as an Earnings Release or a general business update. Given the options, 'ER' (Earnings Release) is the most appropriate fit for a press release detailing operational milestones leading up to a financial report, although it is not a formal financial statement itself. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal statutory report (10-K, IR). It is a direct announcement of business progress.
2022-09-08 English
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ DE THERANEXUS CONCLU AVEC LA SOCIÉTÉ PORTZAMPARC
Transaction in Own Shares Classification · 1% confidence The document is a 'Bilan Semestriel du Contrat de Liquidité' (Half-year report on the liquidity contract) for Theranexus. This document details the transactions (purchases and sales) made by a liquidity provider on behalf of the company over a six-month period. According to the provided definitions, reports detailing the company buying back or selling its own shares (share repurchase/issuance) fall under the 'Transaction in Own Shares' (POS) category. H1 2022
2022-07-18 French
Theranexus publie sa position de trésorerie au 30 juin 2022
Earnings Release Classification · 1% confidence The document is titled "THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 JUIN 2022" (Theranexus Publishes its Cash Position as of June 30, 2022). It explicitly announces the company's cash position as of a specific date (June 30, 2022) and compares it to a previous period (December 31, 2021). This content is a summary of key financial metrics for a specific reporting period, which aligns best with an Earnings Release (ER) which typically provides initial highlights of periodical financial results. It is too brief and focused on highlights to be a full Interim Report (IR). It also announces the next financial publication date (September 27, 2022, for H1 2022 results), reinforcing its nature as a periodic financial update announcement. H1 2022
2022-07-12 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.